JP2002500619A - 置換ビフェニルイソオキサゾールスルホンアミド - Google Patents

置換ビフェニルイソオキサゾールスルホンアミド

Info

Publication number
JP2002500619A
JP2002500619A JP52962097A JP52962097A JP2002500619A JP 2002500619 A JP2002500619 A JP 2002500619A JP 52962097 A JP52962097 A JP 52962097A JP 52962097 A JP52962097 A JP 52962097A JP 2002500619 A JP2002500619 A JP 2002500619A
Authority
JP
Japan
Prior art keywords
dimethyl
oxazolyl
isoxazolyl
biphenyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP52962097A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002500619A5 (https=
Inventor
ムルジサン，ナテサン
バリッシュ，ジョエル・シー
スパーゲル，スティーブン・エイチ
Original Assignee
ブリストル―マイヤーズ・スクイブ・カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ブリストル―マイヤーズ・スクイブ・カンパニー filed Critical ブリストル―マイヤーズ・スクイブ・カンパニー
Publication of JP2002500619A publication Critical patent/JP2002500619A/ja
Publication of JP2002500619A5 publication Critical patent/JP2002500619A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/42—Benzene-sulfonamido pyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP52962097A 1996-02-20 1997-02-20 置換ビフェニルイソオキサゾールスルホンアミド Ceased JP2002500619A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US60397596A 1996-02-20 1996-02-20
US08/603,975 1996-02-20
US75471596A 1996-11-21 1996-11-21
US08/754,715 1996-11-21
US08/799,616 1997-02-13
US08/799,616 US5846990A (en) 1995-07-24 1997-02-13 Substituted biphenyl isoxazole sulfonamides
PCT/US1997/003956 WO1997029748A1 (en) 1996-02-20 1997-02-20 Substituted biphenyl isoxazole sulfonamides

Publications (2)

Publication Number Publication Date
JP2002500619A true JP2002500619A (ja) 2002-01-08
JP2002500619A5 JP2002500619A5 (https=) 2004-11-04

Family

ID=27416891

Family Applications (1)

Application Number Title Priority Date Filing Date
JP52962097A Ceased JP2002500619A (ja) 1996-02-20 1997-02-20 置換ビフェニルイソオキサゾールスルホンアミド

Country Status (9)

Country Link
US (1) US5846990A (https=)
EP (1) EP0921800B1 (https=)
JP (1) JP2002500619A (https=)
AT (1) ATE264324T1 (https=)
AU (1) AU720458B2 (https=)
CA (1) CA2240043A1 (https=)
DE (1) DE69728673T2 (https=)
ES (1) ES2219762T3 (https=)
WO (1) WO1997029748A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008509113A (ja) * 2004-08-05 2008-03-27 サノフイ−アベンテイス Ｎ‐（１ｈ‐インドリル）‐１ｈ‐インドール‐２‐カルボキサミド誘導体、それらの調製法およびそれらの治療学的使用
JP2008526820A (ja) * 2005-01-07 2008-07-24 サノフイ−アベンテイス Ｎ−（ヘテロアリール）−１ｈ−インドール−２−カルボキサミド誘導体及びバニロイドｔｒｐｖ１受容体リガンドとしてのその使用
JP2024523576A (ja) * 2021-07-09 2024-06-28 ヴィコール ファルマ アーベー 新規の選択的アンジオテンシンｉｉ化合物

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541498B2 (en) 1993-05-20 2003-04-01 Texas Biotechnology Benzenesulfonamides and the use thereof to modulate the activity of endothelin
JPH09124620A (ja) 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
EP0904077A4 (en) * 1996-02-20 1999-12-22 Bristol Myers Squibb Co PROCESSES FOR THE PRODUCTION OF BIPHENYL ISOXAZOLE SULFAMIDES
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
AP9901643A0 (en) 1997-04-28 1999-10-02 Texas Biotechnology Corp Sulfonamides for treatment of endothelin-mediated disorders.
AU742506B2 (en) * 1997-10-17 2002-01-03 Eurogene Limited The use of inhibitors of the renin-angiotensin system
DE19813354A1 (de) * 1998-03-26 1999-09-30 Bayer Ag Arylphenylsubstituierte cyclische Ketoenole
US6638937B2 (en) 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
WO2000001389A1 (en) * 1998-07-06 2000-01-13 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
TW526202B (en) 1998-11-27 2003-04-01 Shionogi & Amp Co Broad spectrum cephem having benzo[4,5-b]pyridium methyl group of antibiotic activity
IL144708A0 (en) * 1999-03-19 2002-06-30 Bristol Myers Squibb Co Methods for the preparation of biphenyl isoxazole sulfonamide derivatives
DE60030764T2 (de) * 1999-12-15 2007-09-13 Bristol-Myers Squibb Co. Biphenyl - sulfonamide als duale angiotensin - endothelin - rezeptor - antagonisten
HUP0203935A3 (en) 1999-12-31 2006-02-28 Encysive Pharmaceuticals Inc H Sulfonamides and derivatives thereof that modulate the activity of endothelin, pharmaceutical compositions containing them and their use
JP2004501083A (ja) 2000-04-18 2004-01-15 アゴーロン・ファーマシューティカルズ・インコーポレイテッド プロテインキナーゼを阻害するためのピラゾール
US6639082B2 (en) 2000-10-17 2003-10-28 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
CA2438868A1 (en) * 2001-02-20 2002-09-19 Valentin K. Gribkoff Modulators of kcnq potassium channels and use thereof in treating migraine and mechanistically related diseases
WO2003055482A1 (en) * 2001-12-21 2003-07-10 Novo Nordisk A/S Amide derivatives as gk activators
US7338969B2 (en) 2002-03-08 2008-03-04 Quonova, Llc Modulation of pathogenicity
US7335779B2 (en) * 2002-03-08 2008-02-26 Quonova, Llc Modulation of pathogenicity
BR0312023A (pt) * 2002-06-27 2005-03-22 Novo Nordisk As Composto, composto ativador da glicose cinase, método para evitar a hipoglicemia, uso de um composto, e, composição farmacêutica
EP1551403B1 (en) * 2002-10-10 2009-04-29 Arena Pharmaceuticals, Inc. 5-substituted 2h-pyrazone-3-carboxylic acid derivatives as antilipolytic agents for the treatment of metabolic-related disorders such as dyslipidemia
GB0225548D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Compounds
US7273866B2 (en) * 2002-12-20 2007-09-25 Bristol-Myers Squibb Company 2-aryl thiazole derivatives as KCNQ modulators
US6933308B2 (en) * 2002-12-20 2005-08-23 Bristol-Myers Squibb Company Aminoalkyl thiazole derivatives as KCNQ modulators
US20070197492A1 (en) * 2003-05-06 2007-08-23 Aldo Ammendola Modulation of Pathogenicity
CA2528834A1 (en) * 2003-06-13 2005-02-10 Arena Pharmaceuticals, Inc. 5-substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the nicotinic acid receptor rup25 for the treatment of dyslipidemia and related diseases
BRPI0412003A (pt) * 2003-07-02 2006-08-15 Sugen Inc arilmetil triazol e imidazopirazinas como inibidores de c-met
DE10337497A1 (de) 2003-08-14 2005-03-10 Bayer Cropscience Ag 4-Biphenylsubstituierte-Pyrazolidin-3,5-dion-Derivate
JP4834840B2 (ja) * 2004-01-06 2011-12-14 ノヴォ ノルディスク アー／エス ヘテロアリール尿素およびグルコキナーゼ活性化剤としてのその使用
US7854924B2 (en) * 2004-03-30 2010-12-21 Relypsa, Inc. Methods and compositions for treatment of ion imbalances
BRPI0509331B8 (pt) * 2004-03-30 2021-05-25 Ilypsa Inc uso de uma composição de ligação de sódio
ES2282062T1 (es) 2004-06-04 2007-10-16 Teva Pharmaceutical Industries Ltd. Composicion farmaceutica que contiene irbesartan.
DOP2005000123A (es) * 2004-07-02 2011-07-15 Merck Sharp & Dohme Inhibidores de cetp
ES2382815T3 (es) * 2005-07-08 2012-06-13 Novo Nordisk A/S Dicicloalquilcarbamoil ureas como activadores de glucoquinasa
US7582769B2 (en) * 2005-07-08 2009-09-01 Novo Nordisk A/S Dicycloalkyl urea glucokinase activators
US7884210B2 (en) 2005-07-14 2011-02-08 Novo Nordisk A/S Ureido-thiazole glucokinase activators
CA2624112A1 (en) * 2005-09-30 2007-04-05 Ilypsa, Inc. Methods for preparing core-shell composites having cross-linked shells and core-shell composites resulting therefrom
GB2446077B (en) 2005-09-30 2010-10-13 Ilypsa Inc Methods and compositions for selectively removing potassium ion from the gastrointestinal tract of a mammal
MX2008011227A (es) * 2006-03-03 2009-02-10 Torrent Pharmaceuticals Ltd Receptores antagonistas de accion nueva y doble en los receptores at1 y eta.
WO2008084043A1 (en) * 2007-01-09 2008-07-17 Novo Nordisk A/S Urea glucokinase activators
WO2008084044A1 (en) 2007-01-11 2008-07-17 Novo Nordisk A/S Urea glucokinase activators
UY30892A1 (es) * 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
MX389664B (es) * 2008-08-22 2025-03-20 Vifor Int Ltd Polimeros reticulados de intercambio cationico, composiciones y su uso en el tratamiento de la hipercalcemia
US8337824B2 (en) 2008-08-22 2012-12-25 Relypsa, Inc. Linear polyol stabilized polyfluoroacrylate compositions
US20100104527A1 (en) * 2008-08-22 2010-04-29 Relypsa, Inc. Treating hyperkalemia with crosslinked cation exchange polymers of improved physical properties
US20140057953A1 (en) * 2011-03-03 2014-02-27 Rolf Hartmann Biaryl derivatives as selective 17beta-hydroxysteroid dehydrogenase type 2 inhibitors
JP6475624B2 (ja) 2012-10-08 2019-02-27 レリプサ， インコーポレイテッド 高血圧症及び高カリウム血症を治療するためのカリウム結合剤
CN112040945A (zh) 2018-06-12 2020-12-04 Vtv治疗有限责任公司 葡萄糖激酶激活剂与胰岛素或胰岛素类似物组合的治疗用途
US12391658B2 (en) 2020-02-18 2025-08-19 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof
WO2023224963A1 (en) * 2022-05-16 2023-11-23 Aria Pharmaceuticals, Inc. Dual-acting angiotensin and endothelin receptor antagonists
CN115010621B (zh) * 2022-07-21 2023-11-03 山东百启生物医药有限公司 一种4-溴-3-甲基苯甲腈的合成方法
CN115677511B (zh) * 2022-10-26 2024-06-21 南通华祥医药科技有限公司 一种2,2-二氟丙胺盐酸盐的合成方法

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB804036A (en) * 1956-03-02 1958-11-05 Hoffmann La Roche A process for the manufacture of a sulphanilamide of the isoxazole series
DE1059459B (de) * 1956-09-04 1959-06-18 Shionogi & Co Verfahren zur Herstellung des therapeutisch wertvollen 3-Sulfanilamido-5-methylisoxazols
US2888455A (en) * 1956-09-04 1959-05-26 Shionogi & Co New sulfonamide and process for producing the same
CH364506A (de) * 1956-09-04 1962-09-30 Shionogi & Co Verfahren zur Herstellung des therapeutisch wirksamen 3-Sulfanilamido-5-methyl-isoxazols
GB897440A (en) * 1960-02-08 1962-05-30 Shionogi & Co Improvements in or relating to sulfonamides
GB1473433A (https=) * 1975-10-09 1977-05-11 Banyu Pharmaceutical Co Ltd Hi
US4415496A (en) * 1981-03-23 1983-11-15 Merck & Co., Inc. Bicyclic lactams
EP0076072B1 (en) * 1981-09-24 1987-05-13 BEECHAM - WUELFING GmbH & Co. KG Sulphonamides
US4661479A (en) * 1982-02-19 1987-04-28 Merck And Co., Inc. Bicyclic lactams as antihypertensives
EP0194548A3 (de) * 1985-03-12 1988-08-17 Dr. Karl Thomae GmbH Neue Sulfonylaminoäthylverbindungen, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5464853A (en) * 1993-05-20 1995-11-07 Immunopharmaceutics, Inc. N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US5591761A (en) * 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5594021A (en) * 1993-05-20 1997-01-14 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin
US5514691A (en) * 1993-05-20 1996-05-07 Immunopharmaceutics, Inc. N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5571821A (en) * 1993-05-20 1996-11-05 Texas Biotechnology Corporation Sulfonamides and derivatives thereof that modulate the activity of endothelin
CA2005741C (en) * 1988-12-26 1998-06-02 Hiroyoshi Hidaka Quinoline sulfonoamino compounds having vessel smooth muscle relaxation activity
US5082838A (en) * 1989-06-21 1992-01-21 Takeda Chemical Industries, Ltd. Sulfur-containing fused pyrimidine derivatives, their production and use
IL97219A (en) * 1990-02-19 1995-12-08 Ciba Geigy Ag Biphenyl substituted aliphatic amino compounds process for their preparation and pharmaceutical compositions containing them
CA2079343A1 (en) * 1990-03-30 1991-10-01 Eric E. Allen Substituted pyrazoles, isoxazoles and isothiazoles
US5236928A (en) * 1991-03-19 1993-08-17 Merck & Co., Inc. Imidazole derivatives bearing acidic functional groups at the 5-position, their compositions and methods of use as angiotensin II antagonists
TW270116B (https=) * 1991-04-25 1996-02-11 Hoffmann La Roche
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
UA44686C2 (uk) * 1991-11-05 2002-03-15 Смітклайн Бічем Корпорейшн Похідні індану або індену як антагоністи ендотелінових рецепторів, фармацевтична композиція на їх основі, спосіб їх одержання та спосіб пригнічення ендотелінових рецепторів
SE9103397D0 (sv) * 1991-11-18 1991-11-18 Kabi Pharmacia Ab Nya substituerade salicylsyror
TW224462B (https=) * 1992-02-24 1994-06-01 Squibb & Sons Inc
US5378715A (en) * 1992-02-24 1995-01-03 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
TW215434B (https=) * 1992-03-07 1993-11-01 Hoechst Ag
NZ247440A (en) * 1992-05-06 1995-04-27 Squibb & Sons Inc Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof
US5514696A (en) * 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
WO1993023404A1 (en) * 1992-05-19 1993-11-25 Immunopharmaceutics, Inc. Compounds that modulate endothelin activity
TW287160B (https=) * 1992-12-10 1996-10-01 Hoffmann La Roche
EP0617001B1 (en) * 1993-03-19 2000-01-26 Merck & Co. Inc. Phenoxyphenylacetic acid derivatives
CA2121724A1 (en) * 1993-04-21 1994-10-22 Toshifumi Watanabe Methods and compositions for the prophylactic and/or therapeutic treatment of organ hypofunction
TW394761B (en) * 1993-06-28 2000-06-21 Hoffmann La Roche Novel Sulfonylamino Pyrimidines
DK0634175T3 (da) * 1993-07-15 2001-04-30 Hoffmann La Roche Farmaceutisk kombination, der indeholder en hæmmer af renin-angiotensin-systemet og en endothelin-antagonist
US5965732A (en) * 1993-08-30 1999-10-12 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
GB9504854D0 (en) * 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
GB9409618D0 (en) * 1994-05-13 1994-07-06 Zeneca Ltd Pyridine derivatives
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
CA2168154A1 (en) * 1995-02-06 1996-08-07 Natesan Murugesan Substituted biphenyl sulfonamide endothelin antagonists
DE19509950A1 (de) * 1995-03-18 1996-09-19 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
HUP9802034A3 (en) * 1995-04-04 2000-04-28 Encysive Pharmaceuticals Inc H Thienyl-, furyl-, pyrrolyl- and biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin and use of the compounds
UA58494C2 (uk) * 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
GB9512697D0 (en) * 1995-06-22 1995-08-23 Zeneca Ltd Heterocyclic compounds
EP0904077A4 (en) * 1996-02-20 1999-12-22 Bristol Myers Squibb Co PROCESSES FOR THE PRODUCTION OF BIPHENYL ISOXAZOLE SULFAMIDES
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008509113A (ja) * 2004-08-05 2008-03-27 サノフイ−アベンテイス Ｎ‐（１ｈ‐インドリル）‐１ｈ‐インドール‐２‐カルボキサミド誘導体、それらの調製法およびそれらの治療学的使用
JP2008526820A (ja) * 2005-01-07 2008-07-24 サノフイ−アベンテイス Ｎ−（ヘテロアリール）−１ｈ−インドール−２−カルボキサミド誘導体及びバニロイドｔｒｐｖ１受容体リガンドとしてのその使用
JP2024523576A (ja) * 2021-07-09 2024-06-28 ヴィコール ファルマ アーベー 新規の選択的アンジオテンシンｉｉ化合物

Also Published As

Publication number Publication date
EP0921800B1 (en) 2004-04-14
AU720458B2 (en) 2000-06-01
ATE264324T1 (de) 2004-04-15
WO1997029748A1 (en) 1997-08-21
ES2219762T3 (es) 2004-12-01
EP0921800A4 (en) 2000-12-06
DE69728673T2 (de) 2005-03-31
DE69728673D1 (de) 2004-05-19
EP0921800A1 (en) 1999-06-16
US5846990A (en) 1998-12-08
AU2209897A (en) 1997-09-02
CA2240043A1 (en) 1997-08-21

Similar Documents

Publication Publication Date Title
JP2002500619A (ja) 置換ビフェニルイソオキサゾールスルホンアミド
DE69531918T2 (de) Biphenyl-Isoxazol-Sulfonamide und ihre Verwendung als Endothelin Antagonisten
EP2943483B1 (en) Benzylamine derivatives
EP1945630B1 (en) Pyrazine derivatives as sodium channel modulators for the treatment of pain
JP2006316054A (ja) 高コンダクタンス型カルシウム感受性ｋチャネル開口薬
JP2010526050A (ja) ナトリウムチャンネルモジュレーターとしての２−ピリジンカルボキサミド誘導体
AU2008324172A1 (en) 1, 2, 3-triazole derivatives for use as stearoyl-CoA desaturase inhibitors
JP2008507503A (ja) ピリジン誘導体
CN105829286A (zh) 作为lta4h抑制剂的杂芳基丁酸衍生物
KR20120093425A (ko) 지방산 아미드 가수분해효소의 아조사이클릭 억제제
CN104024250A (zh) 作为痕量胺相关受体(taar)的杂环衍生物
KR20060123739A (ko) 나트륨 채널 차단제로서의 치환된 트리아졸
JP2008533193A (ja) オキシトシン拮抗薬としての置換トリアゾール誘導体
JP2007518686A (ja) 高コンダクタンス型カルシウム感受性ｋチャネル開口薬
TW201245187A (en) Pyrazole derivatives
HK1014709A (en) Substituted isoxazole sulfonamides and their use as endothelin antagonists
TW517057B (en) Substituted biphenyl isoxazole sulfonamides
JP2005504098A (ja) 過剰増殖性障害の処置に有用なピラゾール誘導体
JPH0725854A (ja) 縮合ベンゼンオキシ酢酸誘導体
TW201307294A (zh) 雜環化合物及其用途
HK1216099A1 (en) Benzylamine derivatives
HK1216099B (en) Benzylamine derivatives

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20031211

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20031211

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070731

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20071030

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071116

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20071217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080108

A313 Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20080610

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20080722